Literature DB >> 29256625

The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?

Jason Weatherald1,2, Athénaïs Boucly3,4,5, Sandeep Sahay6, Marc Humbert3,4,5, Olivier Sitbon3,4,5.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29256625     DOI： 10.1164/rccm.201709-1840PP

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN： 1073-449X            Impact factor:   21.405


× No keyword cloud information.
  17 in total

Review 1.  The Use of Risk Assessment Tools and Prognostic Scores in Managing Patients with Pulmonary Arterial Hypertension.

Authors:  Manreet Kanwar; Amresh Raina; Lisa Lohmueller; Jidapa Kraisangka; Raymond Benza
Journal:  Curr Hypertens Rep       Date:  2019-04-25       Impact factor: 5.369

2.  Pulmonary Arterial Remodeling Is Related to the Risk Stratification and Right Ventricular-Pulmonary Arterial Coupling in Patients With Pulmonary Arterial Hypertension.

Authors:  Juan C Grignola; Enric Domingo; Manuel López-Meseguer; Pedro Trujillo; Carlos Bravo; Santiago Pérez-Hoyos; Antonio Roman
Journal:  Front Physiol       Date:  2021-05-03       Impact factor: 4.566

3.  Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With Pulmonary Arterial Hypertension.

Authors:  Raymond L Benza; Manreet K Kanwar; Amresh Raina; Jacqueline V Scott; Carol L Zhao; Mona Selej; C Greg Elliott; Harrison W Farber
Journal:  Chest       Date:  2020-09-01       Impact factor: 9.410

4.  Risk assessment in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.

Authors:  Marc Humbert; Harrison W Farber; Hossein-Ardeschir Ghofrani; Raymond L Benza; Dennis Busse; Christian Meier; Marius M Hoeper
Journal:  Eur Respir J       Date:  2019-06-05       Impact factor: 16.671

5.  Clinical trial design and new therapies for pulmonary arterial hypertension.

Authors:  Olivier Sitbon; Mardi Gomberg-Maitland; John Granton; Michael I Lewis; Stephen C Mathai; Maurizio Rainisio; Norman L Stockbridge; Martin R Wilkins; Roham T Zamanian; Lewis J Rubin
Journal:  Eur Respir J       Date:  2019-01-24       Impact factor: 16.671

Review 6.  The Role of Noninvasive Endpoints in Predicting Long-Term Outcomes in Pulmonary Arterial Hypertension.

Authors:  Samantha L Wronski; Margaret Mordin; Kim Kelley; Rebekah H Anguiano; Peter Classi; Eric Shen; Scott Manaker
Journal:  Lung       Date:  2019-11-13       Impact factor: 2.584

7.  Identification of Cardiac Magnetic Resonance Imaging Thresholds for Risk Stratification in Pulmonary Arterial Hypertension.

Authors:  Robert A Lewis; Christopher S Johns; Marcella Cogliano; David Capener; Euan Tubman; Charlie A Elliot; Athanasios Charalampopoulos; Ian Sabroe; A A Roger Thompson; Catherine G Billings; Neil Hamilton; Kathleen Baster; Peter J Laud; Peter M Hickey; Jennifer Middleton; Iain J Armstrong; Judith A Hurdman; Allan Lawrie; Alexander M K Rothman; Jim M Wild; Robin Condliffe; Andrew J Swift; David G Kiely
Journal:  Am J Respir Crit Care Med       Date:  2020-02-15       Impact factor: 21.405

8.  Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.

Authors:  R James White; Carlos Jerjes-Sanchez; Gisela Martina Bohns Meyer; Tomas Pulido; Pablo Sepulveda; Kuo Yang Wang; Ekkehard Grünig; Shirish Hiremath; Zaixin Yu; Zhang Gangcheng; Wei Luen James Yip; Shuyang Zhang; Akram Khan; C Q Deng; Rob Grover; Victor F Tapson
Journal:  Am J Respir Crit Care Med       Date:  2020-03-15       Impact factor: 21.405

9.  Dart to the target: an alternative bull's eye parametric display for European Society of Cardiology / European Respiratory Society goal-orientated risk reduction strategy in pulmonary arterial hypertension.

Authors:  Cihangir Kaymaz; Ozgur Yasar Akbal; Aykun Hakgor; Hacer Ceren Tokgoz; Seda Tanyeri
Journal:  Pulm Circ       Date:  2018-05-16       Impact factor: 3.017

10.  Risk assessment in patients with functional class II pulmonary arterial hypertension: Comparison of physician gestalt with ESC/ERS and the REVEAL 2.0 risk score.

Authors:  Sandeep Sahay; Adriano R Tonelli; Mona Selej; Zachary Watson; Raymond L Benza
Journal:  PLoS One       Date:  2020-11-11       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.